AdvaMed Cautions FDA Against Rush To “Primary Mode of Action” Rule
This article was originally published in The Gray Sheet
Executive Summary
FDA should issue draft guidance defining "primary mode of action" before moving forward with rulemaking to codify the term, according to AdvaMed
You may also be interested in...
Combo Product Dispute Resolution, Primary Mode Of Action Detailed By OCP
Combination products without regulatory precedent will be assigned to the FDA center with the most expertise in evaluating the products' primary safety and efficacy concerns, according to a proposed rule published in the May 7 Federal Register
Combo Product Dispute Resolution, Primary Mode Of Action Detailed By OCP
Combination products without regulatory precedent will be assigned to the FDA center with the most expertise in evaluating the products' primary safety and efficacy concerns, according to a proposed rule published in the May 7 Federal Register
Combination Products Office Meeting 100% Of Review Goals At Nine Months
FDA's Office of Combination Products coding system and intercenter consultations database are providing the agency with a first look at OCP's early performance on reviews involving more than one center